SynthesisThe European respiratory journal2025
Tuberculosis in adult migrants in Europe: a TBnet consensus statement.
Synthesis in The European respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Tuberculosis disease and infection screening among migrants in the Netherlands 2019-2023: a national retrospective observational study.The Lancet regional health. Europe · 2026Article
- Article
- Screening and treatment practices for tuberculosis infection in Nordic, Baltic and Central European countries and Ukraine in 2023.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Query into Tuberculosis Infection Screening and Management among Pregnant Migrants, Europe.Emerging infectious diseases · 2026Article
- Multidimensional analysis of clinical pharmacist intervention impact on hospital length of stay in pulmonary tuberculosis: a random forest-driven retrospective study.BMC infectious diseases · 2026Article
- Global Burden of Tuberculosis and Drug-Resistant Subtypes Among Women of Childbearing Age from 1990 to 2021, with Projections to 2030.International journal of women's health · 2026Article
- Rifampicin-resistant tuberculosis in Spain.ERJ open research · 2026Article
- Diagnostic algorithms for tuberculosis in Europe: insights from the European Reference Laboratory Network for Tuberculosis (ERLTB-Net).The Lancet regional health. Europe · 2026Review
- At the crossroads of infection and malignancy: the challenge of tuberculosis in migrating populations - Case Report and Epidemiologic Analysis.BMC infectious diseases · 2025Article
- Spatial Analysis of Drug-Resistant Tuberculosis in Colombia (2020-2023): Departmental Rates, Clusters, and Associated Factors.Tropical medicine and infectious disease · 2025Article
- A multinational Delphi consensus on tuberculosis screening of migrants in Europe.ERJ open research · 2025Article
- Tuberculosis at the crossroads: urgent actions for migrant and refugee health in a turbulent era.BMJ global health · 2025Review
- High risk of drug-resistant tuberculosis in IGRA-negative contacts: should preventive treatment be considered?Infection · 2025Article
- Authors' response: Migrant tuberculosis in low-incidence Japan; introduction of pre-entry screening.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Impact of a TB Team on TB Outcomes: A 2016-2024 Pre-Post Study From a Referral Center in Southern Italy.Open forum infectious diseases · 2025Article
- Diagnostic Challenges in Extrapulmonary Tuberculosis: A Single-Center Experience in a High-Resource Setting at a German Tertiary Care Center.Infectious disease reports · 2025Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.Pathogens & immunity · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlobal migration has increased in recent decades owing to war, conflict, persecution and natural disasters, but also secondary to increased opportunities related to work or study. Migrants' risk of tuberculosis (TB) differs depending on migration, socioeconomic status, mode of travel and TB risk in transit, TB incidence and healthcare provision in country of origin. Despite advances in TB care for migrants and new treatment strategies, decisions for managing migrants at risk of TB often rely on expert opinions, rather than clinical evidence.
methodsA systematic literature search was conducted, studies were mapped to different recommendation groups and included studies were synthesised by meta-analysis where appropriate. Current evidence on the diagnosis of active TB in migrants entering the European Union/European Economic Area and UK, including clinical presentation and diagnostic delay, treatment outcomes of drug-susceptible TB, prevalence, and treatment outcomes of multidrug-resistant/rifampicin-resistant TB and TB/HIV co-infection, was summarised. A consensus process was used based on the evidence.
resultsWe documented that migrants had higher vulnerability for TB, including an increased risk of extrapulmonary TB, multidrug-resistant/rifampicin-resistant TB, TB/HIV co-infection and worse TB treatment outcomes compared to host populations. Consensus recommendations include screening migrants for TB/latent TB infection according to country data, a minimal package for TB care in drug-susceptible and multidrug-resistant/rifampicin-resistant TB, implementation of migrant-sensitive strategies and free healthcare and preventive treatment for migrants with HIV co-infection.
conclusionDedicated care for TB prevention and treatment in migrant populations within the European Union/European Economic Area and UK is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.